张天泰，研究员，博士研究生导师。本科、硕士均毕业于兰州大学医学部，获得医学学士和硕士学位。2003年博士毕业于中国药科大学药理学专业。2003年进入中国医学科学院药物研究所从事博士后研究，2006年进入中国医学科学院药物研究所工作，主要从事抗炎免疫药理学及新药发现研究。曾获北京市科学技术奖二等奖2项、中华医学科技奖二、三等奖各1项。

长期从事抗炎免疫药理学及新药发现研究，致力于炎症及自身免疫性疾病的发病机制及免疫调控研究，利用生物分子事件寻找新的药物作用靶点和新药研究。主持研发的治疗自身免疫性疾病化学1类新药--选择性JAK3抑制剂，获得中国及美国专利授权，并于2025年实现了成果转化。

中国足球彩票

1. Yi Zhang^#, Yanqi Han, Ying Sun, Longhui Hao, Yue Gao, Jun Ye, Hongliang Wang, Tiantai Zhang*, Yuling Liu*, Yanfang Yang*. Osteoarthritis: molecular pathogenesis and potential therapeutic options. Signal Transduct Target Ther. 2026, DOI:10.1038/s41392-025-02556-6. (IF=52.7)

2. Gaona Shi^#, Xiang Liu^#, YaziWei^#, Yu Zhou, Xuefeng Gao, Chengjuan Chen, Junjie Yang, Weiwei Wang*, Lan Sun*, Tiantai Zhang*. Immunomodulatory supramolecular hydrogel for rheumatoid arthritis management via adenosine A2A receptor-mediated macrophage remodeling. Bioact Mater. 2026, 58:139-56. (IF=20.3)

3. Yifan Feng^#, Chengjuan Chen^#, Anqi Shao, Qingyang Zhang, Lan Sun*, Haiyu Hu*, Tiantai Zhang*. Recent advances in interleukin1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs. Chin Chem Lett. 2025, 36(12):110936. (IF=8.9)

4. Yifan Feng^#, Chengjuan Chen^#, Anqi Shao, Lei Wu, Haiyu Hu*, Tiantai Zhang*. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer. Acta Pharm Sin B. 2024, 14(12): 5091-105. (IF=14.6)

5. Shuai Shao^#, Chengjuan Chen^#, Gaona Shi, Yu Zhou, Yazi Wei, Lei Wu, Lan Sun*, Tiantai Zhang*. JAK inhibition ameliorated EAE by blocking GM-CSF-driven inflammatory signature of monocytes. Acta Pharm Sin B.  2023, 13(10):4185-201. (IF=14.8)

6. Gaona Shi^#, Yu Zhou, Wenshuai Liu, Chengjuan Chen, Yazi Wei, Xinlong Yan, Lei Wu, Weiwei Wang*, Lan Sun*, Tiantai Zhang*. Bone-derived MSCs encapsulated in alginate hydrogel prevent collagen-induced arthritis in mice through the activation of adenosine A2A/2B receptors in tolerogenic dendritic cells. Acta Pharm Sin B. 2023, 13(6):2778-94. (IF=14.8)

7. Chengjuan Chen^#, Yuan Yin, Gaona Shi, Yu Zhou, Shuai Shao, Yazi Wei, Lei Wu, Dayong Zhang*, Lan Sun*, Tiantai Zhang*. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokines related JAK-STAT signal. Sci Adv. 2022, 8(33):eabo4363. (IF=13.6)

8. Shuai Shao^#, Chengjuan Chen, Gaona Shi, Yu Zhou, Yazi Wei, Ningyu Fan, Yan Yang, Lei Wu, Tiantai Zhang*. Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis. Pharmacol Ther.  2021, 227: 107880. (IF=13.4)

9. Shuai Shao^#, Chengbo Xu^#, Chengjuan Chen, Gaona Shi, Qinglan Guo, Yu Zhou, Yazi Wei, Lei Wu, Jiangong Shi*, Tiantai Zhang*. Divanillyl sulfone suppresses NLRP3 inflammasome activation via inducing mitophagy to ameliorate chronic neuropathic pain in mice. J Neuroinflamm. 2021, 18:142. (IF=9.594)

10. Qinglan Guo^#, Huan Xia^#, Yuzhuo Wu, Shuai Shao, Chengbo Xu, Tiantai Zhang*, Jiangong Shi*. Structure, property, biogenesis, and activity of diterpenoid alkaloids containing a sulfonic acid group from Aconitum carmichaelii. Acta Pharm Sin B. 2020, 10(10):1954-65. (IF=11.614)